Stock News

PerkinElmer Stock Earns 83 Relative Strength Rating; Buys Lifescience Firm BioLegend
PerkinElmer Buys BioLegend for $5.25 Billion in Cash, Stock
PerkinElmer To Acquire Lifescience Firm BioLegend For $5B; Q2 Earnings Beat Estimates
PerkinElmer to buy antibodies maker BioLegend for about $5.3 billion
UPDATE 1-PerkinElmer to buy antibodies maker BioLegend for about $5.3 billion
PerkinElmer stock slips after $5.25 billion cash and stock deal to buy BioLegend
PerkinElmer Board Declares Quarterly Dividend
PerkinElmer Stock Sees Improved Technical Ratings; Still Within Buy Zone

As seen on...